# Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial

> **NCT05156671** · PHASE2 · TERMINATED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 16 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Adrecizumab (HAM 8101)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05156671
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-06
- **Primary completion:** 2023-08-25
- **Final completion:** 2023-11-15
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Due to poor recruitment.
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156671, "Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05156671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*